The Indian Pharmaceutical Market to 2011

Competitive dynamics and major players

Publication Date	July 2007
Publisher	Business Insights
Product Type	Report
Pages	177
ISBN Number	not applicable
Product Code	RBI00156

Buy this product or for assistance call +44 20 7060 7474

PDF £1,730.00$2878 | €1936

FAX Order above formats by FAX

Summary

The Indian Pharmaceutical Market to 2011
Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics' manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams,

enabling Indian pharma companies to experience high market growth.

The Indian Pharmaceutical Market to 2011 provides a detailed analysis of the leading players and discusses how they are planning to sustain growth over the next five years. For each company, this report analyzes current and future therapeutic focus, sales growth, key pipeline products and future growth prospects.

This report will help you to identify the critical success factors that have driven company growth, evaluate diversification opportunities and assess the future potential of each company's R&D portfolio over the next five years.

Key findings of the report...

In 2005, the Indian pharmaceutical industry was valued at $4,660m, representing an increase of 8.3% over year previous sales of $4,304m. A surge in growth is expected to take place between 2006 and 2008, attributable to the opportunities presented by contract research and manufacturing sourcing (CRAMS).
MNCs have a modest representation among the top 20 companies in the Indian pharmaceutical industry. As the market leader, GSK captured a 6.3% share, illustrating the highly fragmented nature of the market.
The re-introduction of the patent regime in 2005 has forced many smaller Indian companies to exit the industry, while others have been forced to re-evaluate existing corporate strategies.
The Indian market has been associated with commodity generics, although a shift in priorities has occurred with many companies increasing their investments in research capabilities and thus establishing themselves as development partners of choice with international companies.

Key questions answered in this report * What are the challenges faced by pharmaceutical companies in the Indian market?

How has the re-introduction of patent regime affected Indian pharmaceutical companies?
What are the market shares for the ten leading Indian companies 2005?
Which of the top ten companies are out performing and under performing in the current market situation and why?
What are the major strengths, weaknesses, opportunities and threats for the market leaders?
Which of the ten companies features the most promising R&D pipeline and how will this impact future growth?

Top five reasons to order your copy today * Gain insights from the best practices of the top 10 Indian pharma companies, by reviewing detailed profiles of current and future drug portfolios, growth strategies and organizational structure.

Assess the pipeline strength of the top 10 Indian Pharma companies and identify future opportunities for growth.
Evaluate how market share of leading companies, such as Ranbaxy, Cipla, Nicholas Piramal, Sun Pharma and Zydus Cadila will change over the next 5 years.
Benchmark forecast performance of the leading players by using analysis of key products in major indications.
Identify which therapy areas offer the greatest opportunity by evaluating the therapeutic focus of the competition.

Content

The Indian pharmaceutical market to
- Executive Summary
- The Indian Pharmaceutical Market
- Company Analysis
- Future Outlook for the Indian pharmaceutical industry
Chapter 1 The Pharmaceutical Market
- Environment in India
- Summary
- Introduction
- Pharmaceutical market environment in India
- Pharmaceutical spending in the Indian market
- Performance of Therapeutic Areas
- Performance of leading companies in the Indian market
- Leading products in the Indian pharmaceutical market
- Factors shaping the Indian pharmaceutical market
Chapter 2 Company analysis
- Summary
- Introduction
- Indian Market analysis by company
- Cipla
- Company Overview
- Geographic Presence
- Product Portfolio Analysis
- Sales focus by therapy area
- Marketed Portfolio
- R&D Pipeline
- Strategic Positioning
- SWOT analysis
- Corporate Strategy
- Ranbaxy
- Company Overview
- Geographic Presence
- Product Portfolio Analysis
- Sales focus by therapy area
- Marketed Portfolio
- R&D Pipeline
- Strategic Positioning
- SWOT analysis
- Corporate Strategy
- Nicholas Piramal
- Company Overview
- Geographic Presence
- Product Portfolio Analysis
- Sales focus by therapy area
- Marketed Portfolio
- R&D Pipeline
- Strategic Positioning
- SWOT analysis
- Corporate Strategy
- Sun Pharmaceuticals
- Company Overview
- Geographic Presence
- Product Portfolio Analysis
- Sales focus by therapy area
- Marketed Portfolio
- R&D Pipeline
- Strategic Positioning
- SWOT analysis
- Corporate Strategy
- Zydus Cadila
- Company Overview
- Geographic Presence
- Product Portfolio Analysis
- Sales focus by therapy area
- Marketed Portfolio
- R&D Pipeline
- Strategic Positioning
- SWOT analysis
- Corporate Strategy
- Dr. Reddy's
- Overview
- Geographic analysis
- Product portfolio analysis
- Sales focus by therapy area
- Marketed portfolio
- R&D pipeline
- Strategic positioning
- SWOT analysis
- Corporate strategy
- Alkem
- Company Overview
- Geographic Presence
- Product Portfolio Analysis
- Sales focus by therapy area
- Marketed Portfolio
- R&D pipeline
- Strategic Positioning
- SWOT analysis
- Corporate strategy
- Lupin
- Company overview
- Geographic analysis
- Product portfolio
- Sales focus by therapy area
- Marketed portfolio analysis
- R&D pipeline
- Strategic positioning
- SWOT analysis
- Corporate strategy
- Aristo
- Company overview
- Geographic analysis
- Product portfolio
- Sales focus by therapy area
- Marketed portfolio analysis
- R&D pipeline
- Strategic Positioning
- SWOT analysis
- Corporate strategy
- Torrent
- Company overview
- Geographic analysis
- Product portfolio
- Sales focus by therapy area
- Marketed portfolio analysis
- R&D pipeline
- Strategic Positioning
- SWOT analysis
- Corporate strategy
- Company forecast sales for the period 2005-11.
Chapter 3 Future Outlook and Competitive Pressures
- Summary
- Introduction
- Competitive pressures being faced by the Indian companies
- Re-introduction of product patent regime in 2005
- Market saturation in the Indian market across major therapy areas
- Increasing competition from other low cost manufacturing markets such as
- China
- Stringent pricing controls on numerous essential medicines
- Future Indian pharmaceutical growth models
- Value versus volume driven market
- Contract Research and Manufacturing Sourcing (CRAMS)
- Contract Manufacturing
- Contract Research and low cost clinical trials
- Mergers and acquisitions
Chapter 4 Appendix
- IMS data
Index
List of Figures
- Figure 1.1: Comparison of pharmaceutical sales in the markets of India, EU5, US, Brazil, Russia,China and Japan, 2005
- Figure 1.2: Comparison of pharmaceutical spending in the markets of India, EU5, and the US,2005
- Figure 1.3: Sales performance of different therapeutic areas in the Indian market, 2005
- Figure 1.4: Competitive Dynamics between the 20 leading companies in India, 2005
- Figure 1.5: Competitive dynamics between leading brands in the Indian market, 2005
- Figure 1.6: Factors shaping the Indian pharmaceutical market
- Figure 2.7: Share of Indian companies by sales, 2005
- Figure 2.8: Cipla's geographic presence, 2005
- Figure 2.9: Cipla therapeutic areas sales performance, 2004-5
- Figure 2.10: Cipla's SWOT Analysis
- Figure 2.11: Cipla's future direction
- Figure 2.12: Ranbaxy geographic presence, 2005
- Figure 2.13: Ranbaxy therapeutic areas sales performance, 2004-05
- Figure 2.14: Ranbaxy's SWOT Analysis
- Figure 2.15: Ranbaxy future direction
- Figure 2.16: NPIL's therapeutic areas sales performance, 2001-05
- Figure 2.17: NPIL's SWOT Analysis
- Figure 2.18: Nicholas Piramal's future direction
- Figure 2.19: Sun Pharmaceutical's geographic presence, 2005
- Figure 2.20: Sun Pharma's therapeutic areas sales performance, 2004-05
- Figure 2.21: Sun Pharma's SWOT Analysis
- Figure 2.22: Sun Pharma's future direction
- Figure 2.23: Zydus Cadila's geographic presence, 2005
- Figure 2.24: Zydus Cadila's therapeutic areas sales performance, 2004-05
- Figure 2.25: Zydus: SWOT Analysis
- Figure 2.26: Zydus Cadila's future direction
- Figure 2.27: Dr. Reddy's geographic presence, 2005
- Figure 2.28: Competitive dynamics of Dr. Reddy's key therapy areas, 2005
- Figure 2.29: Dr. Reddy's SWOT analysis
- Figure 2.30: Dr. Reddy's future direction
- Figure 2.31: Alkem's geographic presence, 2005
- Figure 2.32: Alkem's performance by therapeutic area, 2001-05
- Figure 2.33: Alkem's SWOT analysis
- Figure 2.34: Alkem's future direction
- Figure 2.35: Lupin's geographic presence, 2005
- Figure 2.36: Competitive dynamics of Lupin's key therapy areas, 2005
- Figure 2.37: Lupin's SWOT analysis
- Figure 2.38: Lupin's future direction
- Figure 2.39: Competitive dynamics of Aristo's key therapy areas, 2005
- Figure 2.40: Aristo's SWOT analysis
- Figure 2.41: Torrent's geographic presence, 2005
- Figure 2.42: Competitive dynamics of Torrent's key therapy areas, 2005
- Figure 2.43: Torrent's SWOT analysis
- Figure 2.44: Torrent's future direction
- Figure 3.45: Forecast future trends of Indian pharmaceutical companies
- Figure 3.46: Future growth opportunities for Indian pharmaceutical companies
List of Tables
- Table 1.1: Breakdown of the Indian pharmaceutical market by therapy area, 2001-05
- Table 1.2: Sales of leading pharmaceutical companies in India, 2004-05
- Table 1.3: Leading brands in the Indian market, 2004-05
- Table 2.4: Sales of leading Indian pharmaceutical companies, 2004-05
- Table 2.5: Breakdown of the Cipla's revenues by therapy area, 2001-05
- Table 2.6: Leading brands in Cipla's marketed portfolio, 2004-05
- Table 2.7: Cipla's Commercial Agreements 2001-2007
- Table 2.8: Breakdown of the Ranbaxy's revenues by therapy area, 2001-05
- Table 2.9: Leading brands in Ranbaxy's marketed portfolio, 2004-05
- Table 2.10: Ranbaxy's R&D product pipeline, 2006
- Table 2.11: Ranbaxy's Commercial Agreements 2001-2007
- Table 2.12: Breakdown of the Nicholas Piramal's revenues by therapy area, 2001-05
- Table 2.13: Leading brands in NPIL's marketed portfolio, 2004-05
- Table 2.14: NPIL's R&D product pipeline, 2006
- Table 2.15: NPIL's Commercial Agreements 2001-2007
- Table 2.16: Breakdown of the Sun Pharma's revenues by therapy area,
- Table 2.17: Leading brands in Sun Pharma's marketed portfolio, 2004-05
- Table 2.18: Sun Pharma's R&D product pipeline, 2006
- Table 2.19: Sun Pharma's Commercial Agreements 2001-2007
- Table 2.20: Breakdown of Zydus Cadila's revenues by therapy area, 2001-05
- Table 2.21: Leading brands in Zydus Cadila's marketed portfolio, 2004-05
- Table 2.22: Zydus Cadila's R&D product pipeline, 2006
- Table 2.23: Zydus Cadila's Commercial Agreements 2001-2007
- Table 2.24: Breakdown of Dr. Reddy's revenues by therapy area, 2001-05
- Table 2.25: Leading brands in Dr. Reddy's marketed portfolio, 2004-05
- Table 2.26: Dr. Reddy's R&D product pipeline, 2006
- Table 2.27: Dr. Reddy's corporate agreements 2001-2006
- Table 2.28: Breakdown of Alkem's revenues by therapy area, 2001-05
- Table 2.29: Leading brands in Alkem's marketed portfolio, 2004-05
- Table 2.30: Alkem's corporate agreements 2001-2006
- Table 2.31: Breakdown of Lupin's revenues by therapy area, 2001-05
- Table 2.32: Leading brands in Lupin's marketed portfolio, 2004-05
- Table 2.33: Lupin's R&D product pipeline, 2006
- Table 2.34: Lupin's corporate agreements 2001-2006
- Table 2.35: Breakdown of Aristo's revenues by therapy area, 2001-05
- Table 2.36: Leading brands in Aristo's marketed portfolio, 2004-05
- Table 2.37: Breakdown of Torrent's revenues by therapy area, 2001-05
- Table 2.38: Leading brands in Torrent's marketed portfolio, 2004-05
- Table 2.39: Torrent's R&D product pipeline, 2006
- Table 2.40: Torrent's corporate agreements 2001-2006
- Table 2.41: Company sales forecasts for the Indian market,